✦ LIBER ✦

Adjuvant MAGE-A3 Immunotherapy in Resected Non-Small-Cell Lung Cancer: Phase II Randomized Study Results

✍ Scribed by Vansteenkiste, J.; Zielinski, M.; Linder, A.; Dahabreh, J.; Gonzalez, E. E.; Malinowski, W.; Lopez-Brea, M.; Vanakesa, T.; Jassem, J.; Kalofonos, H.; Perdeus, J.; Bonnet, R.; Basko, J.; Janilionis, R.; Passlick, B.; Treasure, T.; Gillet, M.; Lehmann, F. F.; Brichard, V. G.

Book ID: 121425991
Publisher: American Society of Clinical Oncology
Year: 2013
Tongue: English
Weight: 294 KB
Volume: 31
Category: Article
ISSN: 0732-183X
DOI: 10.1200/JCO.2012.43.7103

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Adjuvant chemotherapy for completely res

Adjuvant chemotherapy for completely resected stage III non-small-cell lung cancer: Results of a randomized prospective study

📂 Article 📅 1994 🏛 Elsevier Science 🌐 English ⚖ 303 KB

A randomized phase III trial of adjuvant

A randomized phase III trial of adjuvant treatment for resected non-small cell lung cancer in Japan

✍ Yukito Ichinose 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 294 KB

Randomized Study of Adjuvant Chemotherap

Randomized Study of Adjuvant Chemotherapy for Completely Resected Stage I, II, or IIIA Non-Small-Cell Lung Cancer

✍ Scagliotti, G. V. 📂 Article 📅 2003 🏛 Oxford University Press 🌐 English ⚖ 142 KB

6514 ORAL Adjuvant therapy in stage IB/I

6514 ORAL Adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC): final results of a multi-center, double-blind, randomized, placebo-controlled Phase II study evaluating the MAGE-A3 cancer immunotherapeutic

✍ Vansteenkiste, J.; Zielinski, M.; Linder, A.; Dahabre, J.; Esteban, E.; Malinows 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 59 KB

Phase II study of docetaxel and vinorelb

Phase II study of docetaxel and vinorelbine as adjuvant chemotherapy for resected non-small cell lung cancers

✍ Chaft, Jamie E.; Rekhtman, Natasha; Sima, Camelia S.; Rusch, Valerie; Kris, Mark 📂 Article 📅 2013 🏛 Springer 🌐 English ⚖ 229 KB

MAGE-A3 Antigen-Specific Cancer Immunoth

MAGE-A3 Antigen-Specific Cancer Immunotherapeutic (ASCI) as adjuvant therapy in resected stage IB/II non-small cell lung cancer (NSCLC): from proof-of-concept to phase III trial (MAGRIT)

✍ Eisen, T.; Vansteenkiste, J.; Zielinski, M.; Linder, A.; Dahabreh, J.; Jassem, J 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 66 KB